Adentri

Adentri

CVT-124 Cardiology An adenosine A1 receptor antagonist in clinical trials in Pts with CHF. See Congestive heart failure.
References in periodicals archive ?
Adentri Will Earn Decision Resources' Clinical Gold Standard Status for Acute Heart Failure in 2012, According to a New Report from Decision Resources
Clinical data and the opinions of interviewed thought leaders indicate that Biogen Idec's Adentri has advantages in this attribute over nitroglycerin, the benchmark therapy in the market.
The trial will evaluate ADENTRI, which is being developed under a licensing agreement with CV Therapeutics (Nasdaq: CVTX), or placebo in addition to standard of care in approximately 900 patients in 21 countries globally, including the United States.
The TRIDENT-1 (TReatment with Intravenous BG9928 for patients with acutely DEcompensated heart failure and reNal insufficiency Trial) study is a Phase III randomized, multi-center, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of IV ADENTRI dosed up to five days on body weight in ADHF patients with impaired renal function.
In previous clinical studies, ADENTRI has exhibited the potential to optimize fluid management without harmful effects on renal function.
2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Biogen Idec's Adentri and Merck's rolofylline are the most promising therapies in development for acute heart failure, according to surveyed experts.
The new Pharmacor report entitled Acute Heart Failure finds that the launch of Adentri and rolofylline, along with EKR Therapeutics' ularitide, will be the primary drivers of growth in the acute heart failure drug market over the next decade.
Results showed that administration of oral ADENTRI for 10 days, in addition to standard heart failure therapy, was well tolerated and resulted in clinically significant increases in sodium excretion while preserving renal function.
We are excited to have these data published showing the potential of ADENTRI in patients with heart failure.
In addition, Biogen has ongoing Phase II studies for Amievive for treatment of moderate to severe psoriasis and Adentri, a novel diuretic agent.
Ranexa, regadenoson, tecadenoson, Adentri and CVT-6883 have not been approved for marketing by the FDA or any foreign regulatory authorities.
Ranexa, regadenoson, tecadenoson and Adentri have not been approved for marketing by the FDA or any foreign regulatory authorities.
Full browser ?